J&J: positive trial for dexamethasone
(CercleFinance.com) - Johnson & Johnson presents results from a Phase 2 study, showing that prophylaxis with 8 mg dexamethasone reduced the incidence of infusion-related reactions (IRR) with Rybrevant by a factor of three in patients with non-small cell lung cancer (NSCLC).
The rate of IRRs fell from 67.4% to 22.5%. In addition, no serious events were reported, and side effects were minor, the laboratory points out.
"These data offer important information that can help improve the patient experience with intravenous amivantamab therapy," said Gilberto Lopes, M.D., Associate Director of Global Oncology at Sylvester Comprehensive Cancer Center and a member of the Miller School of Medicine at the University of Miami.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The rate of IRRs fell from 67.4% to 22.5%. In addition, no serious events were reported, and side effects were minor, the laboratory points out.
"These data offer important information that can help improve the patient experience with intravenous amivantamab therapy," said Gilberto Lopes, M.D., Associate Director of Global Oncology at Sylvester Comprehensive Cancer Center and a member of the Miller School of Medicine at the University of Miami.
Copyright (c) 2024 CercleFinance.com. All rights reserved.